December industry round-up: Aetion chosen by EMA to conduct safety and efficacy research

6 Jan 2022

Written by The Evidence Base

COVID-19 Health technology assessment Industry Updates Medical devices, pharmaceuticals and vaccines Methodology Real-world evidence Stakeholder engagement

This month, Aetion (NY, USA) works with the EMA (Amsterdam, The Netherlands) on treatment safety and efficacy studies, Tempus (IL, USA) collaborates with Janssen R&D (Beerse, Belgium) to advance oncology treatments, IQVIA (NC, USA) accelerates decentralized trial efforts by introducing mobile Research Nursing and Phlebotomy units, Radicle Science (CA, USA) announces the preliminary findings of the largest RWE study on CBD and the EMA approved an increase in manufacturing capacity for three COVID-19 vaccines. In this latest instalment of our regular monthly column, we summarize a selection of key real-world evidence (RWE)-focused industry developments that have taken place over the...